1068657-02-2

Upstream product

• 103-04-8 (phenylthio)acetic acid 
• 821-11-4 1,4-butenediol 
• 66074-00-8 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 

Downstream Products

• 1190065-21-4 4-[2-oxido-3-(phenylsulfonyl)-1,2,5-oxadiazol-4-yloxy]but-2-enyl 4-(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)benzoate 
• 1446816-82-5 4-((4-((3-carboxypropanoyl)oxy)-2-butenyl)oxy)-3-benzenesulfonyl-1,2,5-oxadiazole-2-oxide 
• 1206200-04-5 4-(4-(4'-((3-butyl-1-(2,6-dichlorophenyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)methyl)biphenylcarbonyloxy)but-2-enyloxy)-3-(phenylsulfonyl)-[1,2,5]oxadiazole 2-oxide 
• 1236359-16-2 C₁₉H₂₃N₃O₉S 

Relevant academic research and scientific papers

Aurovertin B derivative as well as preparation method and application thereof

The invention provides an aurovertin B derivative, a preparation method of the aurovertin B derivative, and an application of the aurovertin B derivative in the preparation of a medicine for treatingtriple negative breast cancer. The polarity of the aurov

Parthenolide-benzene sulfonyl furazan derivative as well as salt, preparation method and application thereof

The invention provides a parthenolide benzene sulfonyl furazan derivative shown as a formula (I), salt and a preparation method thereof, and application thereof in the preparation of anti-cancer drugs.

Design and synthesis of novel senkyunolide analogues as neuroprotective agents

A class of senkyunolide analogues bearing benzofuranone fragment were designed, synthesized and evaluated for their neuroprotective effect in models of oxygen glucose deprivation (OGD) and oxidative stress. All tested compounds showed neuroprotection profile based on the cell viability assay. In particular, derivatives 1f–1i possessing furoxan-based nitric oxide releasing functionality exhibited significant biological activities in OGD models. More importantly, compound 1g containing short linker with furoxan displayed the most potent neuroprotection at the concentration of 100 μM (cell survival up to 145.2%). Besides, 1g also showed the middle level neuroprotective effect in model of oxidative stress.

Nitric oxide-donating derivatives of hederacolchiside A1: Synthesis and biological evaluation in vitro and in vivo as potential anticancer agents

A series of nitric oxide (NO) donating derivatives of hederacolchiside A1bearing triterpenoid saponin motif were designed, synthesized and evaluated for their anticancer activity. All of the tested furoxan-based NO releasing compounds showed significant proliferation inhibitory activities. Especially compound 6a exhibited strong cytotoxicity (IC50= 1.6–6.5 μM) against four human tumor cell lines (SMMC-7721, NCI-H460, U251, HCT-116) in vitro and the highest level of NO releasing. Furthermore, compound 6a was revealed low acute toxicity to mice and weak haemolytic activity with potent tumor growth inhibition against mice H22 hepatocellular cells in vivo (51.5%).

Synthesis and bioactivity of furoxan-based nitric oxide-releasing colchicine derivatives as anticancer agents

A series of novel nitric oxide-donating colchicine derivatives (9a-j) were synthesized by coupling furoxan with N-methyl colchiceinamide through an appropriate spacer arm and their cytotoxicity against four human cancer cell lines in vitro were evaluated by MTT method. It was found that many of the derivatives displayed significant activity, particularly, compound 9f showed more potent cytotoxic activities than colchicine.

Synthesis and biological evaluation of nitric oxide-donating thalidomide analogues as anticancer agents

In search of more potent anticancer agents, 15 nitric oxide (NO)-donating thalidomide analogues, 6a, 6b, 8a-8e, and 13a-13h, were designed and synthesized. Cytotoxicity of these compounds was evaluated in vitro against three human tumor cell lines (HepG2, A549, and PC-3). The results indicated that 13a-13d exhibited notable anticancer activities comparable to or stronger than that of 5-fluorouracil (5-FU). Structure-activity relationships were also discussed, based on the experimental data obtained. Generally, the cytotoxic activity of target compounds is closely related to the type of NO donors, and the length of the spacers connecting to NO donors also appears important for the bioactivities.